Anti-obesity effect of an isoflavone fatty acid ester on Obese mice induced by high fat diet and its potential mechanism

Lipids in Health and Disease

Volumn 9, Issue 1, 2010, Pages

  Yao, Yao ^a   Li, Xiao Bo ^b   Zhao, Wei ^b   Zeng, Yan Yan ^a   Shen, Hong ^a   Xiang, Hua ^b   Xiao, Hong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4' METHOXY DAIDZEIN 7 FATTY ACID ESTER; ANTILIPEMIC AGENT; FATTY ACID ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL NICOTINATE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; ISOFLAVONE DERIVATIVE;

3T3-L1 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; BODY MASS; BODY WEIGHT LOSS; C57BL 6 MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DIET INDUCED OBESITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FAT MASS; FLOW CYTOMETRY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIVER SLICE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROADIPOCYTE; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; APOPTOSIS; BODY WEIGHT; C57BL MOUSE; CELL STRAIN 3T3; CYTOLOGY; FAT INTAKE; LIPID METABOLISM; LIVER; METABOLISM; MOUSE MUTANT; OBESITY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; APOPTOSIS; BODY WEIGHT; DIETARY FATS; ISOFLAVONES; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY;

EID: 77952316885     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-49     Document Type: Article

References (56)

1. Formiguera X, Canton A: Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 2004, 18:1125-1146.
2. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol, Metab 2004, 89:2595-2600.
3. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J, Hartzell DL, Hamrick MW, Baile CA: Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr 2006, 136:409-414.
4. Vettor R, Rossato M: The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from Rimonabant In Obesity (RIO) trials. International Congress Series 2007, 1303:146-154.
5. Padwal R S, Majumdar S R: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
6. Sayin T, Güldal M: Sibutramine: Possible cause of a reversible cardiomyopathy. International Journal of Cardiology 2005, 99:481-482.
7. Lin J, Della-Fera MA, Baile CA: Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res 2005, 13:982-990.
8. Xie L, O'Reilly C P: Adiponectin and leptin are secreted through distinct trafficking pathways in adipocytes. Biochimica et Biophysica Acta 2008, 1782:99-108.
9. Fasshauer M, Kralisch S: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 2003, 301:1045-1050.
10. Araki S, Dobashi K: N-acetylcysteine attenuates TNF-a induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sciences 2006, 79:2405-2412.
11. Tanaka Masaki, Nozaki Maiko: Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochemical and Biophysical Research Communications 2007, 359:194-201.
12. Hargrave KM, Meyer BJ, Li C, Azain MJ, Baile CA, Miner JL: Influence of dietary conjugated linoleic Acid and fat source on body fat and apoptosis in mice. Obes Res 2004, 12:1435-1444.
13. Kim OK: Ginseng saponin-Re and Coix lachrymajobi var. mayuen regulate obesity related genes expressions, TNF-alpha, leptin, lipoprotein lipase and resistin in 3T3-L1 adipocytes. Korean J Life Sci 2007, 17:1523-1532.
14. Cho EJ, Rahman A, Kim SW, Baek YM, Hwang HJ, Oh JY, Hwang HS, Lee SH, Yun JW: Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes. J Microbiol Biotechnol 2008, 18:80-87.
15. Tang QQ, Otto TC, Lane MD: Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA 2003, 100:44-49.
16. Saltiel AR, Kahn CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
17. Cederroth CR, Nef S: Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 2009, 304(1-2):30-42.
18. Song WO, Chun OK, Hwang I, Shin HS, Kim BG, Kim KS, Lee SY, Shin D, Lee SG: Soy Isoflavones as Safe Functional Ingredients. J Med Food 2007, 10:571-580.
19. Veitch NC: Isoflavonoids of the Leguminosae. Nat Prod Rep 2007, 24:417-464.
20. Ørgaard A, Jensen L: The Effects of Soy Isoflavones on Obesity. Exp Bio Med 2008, 233:1066-1080.
21. Havel PJ: Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc 2000, 59:359-371.
22. Jason CG, Halford: Pharmacotherapy for obesity. Appetite 2006, 46:6-10.
23. Scheen AJ, Finer N, Hollander P, Jensen MD, van Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patient with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
24. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet 2007, 370:1706-1713.
25. Levy P, Fried M, Santini F, Fines: The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg 2007, 17:1248-1256.
26. Ono Y, Hattor E: Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats. Journal of Ethnopharmacology 2006, 106:238-244.
27. Schittmayer M, Birner-Gruenberger R: Functional proteomics in lipid research: Lipases, lipid droplets and lipoproteins. Proteomics 2009.
28. Rezaee F, Casetta B: Proteomic analysis of high-density lipoprotein. Proteomics 2006, 2:721-730.
29. Lupien P, Brun D, Gagne C, Moorjani S, Bielman P, Julien P: Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. The Canadian Journal of Cardiology 1991, 7:27-33.
30. Fruchart JC, Brewer HB Jr, Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. The American Journal of Cardiology 1998, 81:912-917.
31. Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT: Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Experimental and Molecular Medicine 2002, 34:485-492.
32. Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT: Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochemical and Biophysical Research Communications 2003, 302:29-34.
33. Jeong S, Han M, Lee H, Kim M, Nicol CJ, Kim BH, Choi JH, Oh GT, Yoon M: Effects of fenofibrate on high fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 2004, 53:1284-1289.
34. Friedman JM, Halas JL: Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
35. Margetic S, Gazzola C, Pegg GG, Hill RA: Leptin: a review of its peripheral actions and interactions. Int J obes Relat, Metab Disord 2002, 26:1407-1433.
36. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB: Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 2005, 493:63-71.
37. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW: Central nervous system control of food intake and body weight. Nature 2006, 443:289-295.
38. Bates SH, Myers MG Jr: The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 2003, 14:447-452.
39. Chen Y, Heiman M: Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept 2000, 92:113-119.
40. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
41. Considine RV, Caro JF: Leptin and the regulation of body weight. Int J Biochem Cell Biol 1997, 29:1255-1272.
42. Jacobson L: Middle-aged C57BL/6 mice have impaired responses to leptin that are not improved by calorie restriction. Am J Physiol 2002, 282:E786-793.
43. Scarpace PJ, Matheny M, Zhang Y, Tumer N, Frase CD, Shek EW: Central leptin gene delivery evokes persistent leptin signal transduction in young and aged-obese rats but physiological responses become attenuated over time in aged-obese rats. Neuropharmacology 2002, 42:548-561.
44. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS: Two defects contribute to hypothalamic leptin resistance in mice with dietinduced obesity. J Clin Invest 2000, 105:1827-1832.
45. Lin L, Martin R, Schaffhauser AO, York DA: Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol 2001, 280:504-509.
46. Lin S, Thomas TC, Storlien LH, Huang XF: Development of high fat dietinduced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 2000, 24:639-646.
47. Mantzoros CS, Liolios AD, Titos NA: Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res 1998, 6:179-186.
48. Soderberg S, Ahren B, Jansson JH: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999, 246:409-418.
49. Wallace AM, McMahon AD, Packard CJ: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001, 104:3052-3056.
50. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44:1819-1824.
51. Reilly MP, Iqbal N, Schutta M: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Meta 2004, 89:3872-3878.
52. Evans M, Lin X, Odle J, McIntosh M: Trans-10, cis-12 conjugated linoleic acid increases fatty acid oxidation in 3T3-L1 preadipocytes. J Nutr 2002, 132:450-455.
53. Jeon T, Hwang SG, Hirai S, Matsui T, Yano H, Kawada T, Lim BO, Park DK: Red yeast rice extracts suppress adipogenesis by down-regulating adipogenic transcription factors and gene expression in 3T3-L1 cells. Life Sci 2004, 17:3195-3203.
54. Zou C, Shao J: Role of adipocytokines in obesity-associated insulin resistance. Journal of Nutritional Biochemistry 2008, 19:277-286.
55. Prins JB, O'Rahilly S: Regulation of adipose cell number in mature adipocytes. Clin Sci (Lond) 1997, 92:3-11.
56. Farme SR: Transcriptional control of adipocyte formation. Cell Metab 2006, 4:263-273.